Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.
Format: Microsoft PowerPoint (.ppt)
File Size: 542 KB
Released: June 12, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings